Igm Biosciences Inc Net Income per Employee (IGMS), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Igm Biosciences Inc   (NASDAQ: IGMS)
 

Igm Biosciences Inc Net Income per Employee

IGMS's Quarterly Results, Trends, Rankings, Statistics
Igm Biosciences Inc recorded a cumulative net loss of $-53 million during 12 month ending in the second quarter 2025.
The Healthcare sector has seen employees of 103 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 3136, from total ranking in previous quarter at 3340.


What is Income per Employee Ratio?






IGMS Net Income per Employee (Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
(Dec 31 2024)
IV. Quarter
(Sep 30 2024)
III. Quarter
(Jun 30 2024)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -238,326 -887,817 -874,085 -981,442 -983,938
IGMS's Total Ranking # 3136 # 3340 # 2827 # 2329 # 2949
Seq. Net Income Change - - - - -


IGMS Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 104
Healthcare Sector # 356
Overall Market # 3136

Net Income per Employee Statistics
High Average Low
$ -45,411 $ -729,151 $ -1,100,071
(Sep 30 2019)   (Dec 31 2023)







Companies with similar Income per Employee for 12 month ending Jun 30 2025, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2025Number of Employees Jun 30 2025


Date modified: 2026-09-08T18:11:09+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.